7,542 reports of this reaction
1.5% of all DICLOFENAC reports
#12 most reported adverse reaction
PEMPHIGUS is the #12 most commonly reported adverse reaction for DICLOFENAC, manufactured by Altaire Pharmaceuticals Inc.. There are 7,542 FDA adverse event reports linking DICLOFENAC to PEMPHIGUS. This represents approximately 1.5% of all 487,456 adverse event reports for this drug.
Patients taking DICLOFENAC who experience pemphigus should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PEMPHIGUS is a less commonly reported adverse event for DICLOFENAC, but still significant enough to appear in the safety profile.
In addition to pemphigus, the following adverse reactions have been reported for DICLOFENAC:
The following drugs have also been linked to pemphigus in FDA adverse event reports:
PEMPHIGUS has been reported as an adverse event in 7,542 FDA reports for DICLOFENAC. This does not prove causation, but indicates an association observed in post-market surveillance data.
PEMPHIGUS accounts for approximately 1.5% of all adverse event reports for DICLOFENAC, making it a notable side effect.
If you experience pemphigus while taking DICLOFENAC, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.